Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 10/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.49 |
| ▸ | RORC | P51449 | 3/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557228 | 0.90 | REN (0.53) | RENKCNH2CYP3A4RORCALK | |
| SCHEMBL555815 | 0.90 | REN (0.61) | RENKCNH2CYP3A4RORCALK | |
| SCHEMBL533844 | 0.89 | REN (0.63) | RENKCNH2CYP3A4RORCALK | |
| SCHEMBL555594 | 0.89 | REN (0.63) | RENKCNH2CYP3A4RORCALK | |
| SCHEMBL555742 | 0.89 | REN (0.62) | RENKCNH2CYP3A4RORCALK | |
| SCHEMBL556767 | 0.89 | REN (0.48) | RENKCNH2CYP3A4RORCALK | |
| SCHEMBL556026 | 0.87 | REN (0.56) | RENKCNH2CYP3A4RORCALK | |
| SCHEMBL556815 | 0.87 | REN (0.52) | RENKCNH2CYP3A4RORCALK | |
| SCHEMBL557036 | 0.86 | REN (0.60) | RENKCNH2CYP3A4RORC | |
| SCHEMBL555970 | 0.85 | REN (0.50) | RENKCNH2CYP3A4RORCALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885KCNH2 1198/4885CYP3A4 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.